StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.64+0.16 (+2.47%)

Close on Nov 18, 2026Market cap $113.58MP/E –Yield –

Atrium Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$15.32M+298.3%
Q2 FY2026Jun 30, 2026$3.00M+91.0%
Q1 FY2026Mar 31, 2026$19.64M–
Q3 FY2025Sep 30, 2025$12.34M–
Q2 FY2025Jun 30, 2025$3.85M–
Q1 FY2025Mar 31, 2025$1.57M–

More Atrium Therapeutics figures

See a number that looks wrong?